

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

MC-38

RRID:CVCL_B288

Type: Cell Line

Proper Citation

ABM Cat# T8291, RRID:CVCL_B288

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B288

Proper Citation: ABM Cat# T8291, RRID:CVCL_B288

Description: Cell line MC-38 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Female

Disease: Mouse colon adenocarcinoma

Defining Citation: [PMID:1149045](#), [PMID:1255804](#), [PMID:16320114](#), [PMID:25277546](#), [PMID:25428506](#), [PMID:25434994](#), [PMID:36969213](#)

Comments: Caution: The authors of PubMed=25434994 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line MCA38. Their submitted DNA sequence (KM820832.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 406'. Miscellaneous: Comparative analysis of MC38 cells obtained from Kerafast (MC38-K) and from Leiden University Medical Center (MC38-L) shows major differences in term of mutations and mRNA expression (PubMed=36969213).

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: MC-38

Synonyms: MCA-38, MCA 38, MCA38, MC38, MC-38 B/6, Mouse Colon 38, Murine Carcinoma-38, Colon-38, Colon 38, Colon38, C38

Cross References: BTO:BTO_0004163, ABM:T8291, CCRID:1101MOU-PUMC000523, ChEMBL-Cells:ChEMBL3307696, ChEMBL-Targets:ChEMBL612821, CLS:305223, Kerafast:ENH204-FP, Lonza:893, Millipore:SCC172, PubChem_Cell_line:CVCL_B288, Ubigen:YC-A002, Wikidata:Q54904168

ID: CVCL_B288

Vendor: ABM

Catalog Number: T8291

Record Creation Time: 20250423T101217+0000

Record Last Update: 20260830T002746+0000

Ratings and Alerts

No rating or validation information has been found for MC-38.

No alerts have been found for MC-38.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1489 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lim SK, et al. (2026) Targeted computational design of an interleukin-7 superkine with enhanced folding efficiency and immunotherapeutic efficacy. eLife, 14.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. Molecular cancer therapeutics, 25(3), 457.

Chen W, et al. (2026) USP35 Acts as a Deubiquitinating Enzyme for ID3 to Promote Immune Escape in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e16588.

M??dl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. Cancer research, 86(1), 80.

Liang X, et al. (2026) Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. Cell death discovery, 12(1), 92.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell reports. Medicine, 7(4), 102706.

Wang X, et al. (2026) Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. Cancer cell, 44(3), 658.

- Mosley SR, et al. (2026) Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer. *Cell reports*, 45(3), 117012.
- Cornelius P, et al. (2026) Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth. *Frontiers in oncology*, 16, 1751681.
- Tao G, et al. (2026) Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. *Journal of translational medicine*, 24(1).
- Malagola E, et al. (2026) Loss of proton-sensing TDAG8 increases tumor progression in mouse models of colon cancer. *Molecular oncology*.
- Mizuno N, et al. (2026) Characterization of a transmembrane-activating STING agonist using genetically humanized mice. *Cell reports*, 45(6), 117475.
- Jiang Y, et al. (2026) Ultrasmall Au₁₀₋₁₂ Nanoclusters: A Novel Platform for ²²³Ra-Targeted Tumor ??-Therapy. *Exploration (Beijing, China)*, 6(2), 70144.
- Nie H, et al. (2026) GBP2 enhances anti-PD-L1 response in colorectal cancer via GSDMD-mediated YAP nuclear translocation by non-pyroptotic. *Oncogene*, 45(25), 2452.
- Lin Y, et al. (2026) Integrin CD11b/CD18 reprograms macrophage polarization by suppressing ERK/STAT3 signaling to enhance antitumor immunity in colitis-associated colorectal cancer. *Journal for immunotherapy of cancer*, 14(6).
- Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. *Cancer research*, 86(1), 116.
- Zhang B, et al. (2026) Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine-Driven Immune Suppression in Colorectal Cancer. *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*, 13(5), e13986.
- Pan D, et al. (2026) DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. *Cancer research*, 86(12), 3026.
- Duan X, et al. (2026) DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. *Cancer immunology research*, 14(6), 900.
- Kim Y, et al. (2026) Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells. *ACS nano*, 20(12), 9925.